ArticleMicrobial biotechnology2025
Production of the Antimicrobial Roseoflavin With Genetically Engineered Corynebacterium glutamicum.
Article in Microbial biotechnology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Feasibility and Safety of Washed Microbiota Transplantation as Salvage Therapy for Refractory Non-CDI Gut Pathogens in Critically Ill Patients.Microbial biotechnology · 2026Article
- Engineering of Corynebacterium glutamicum for biosynthesis of the pharmaceutically active N-acetyltyramine: establishing and optimizing de novo production.Journal of biological engineering · 2026Article
- Production of the Antimicrobial Roseoflavin With Genetically Engineered Corynebacterium glutamicum.Microbial biotechnology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
The global rise of drug-resistant bacterial infections underscores an urgent demand for novel antimicrobial agents. Roseoflavin, a naturally occurring riboflavin analog, has emerged as a promising candidate for drug development. In this study, the industrial workhorse Corynebacterium glutamicum was metabolically engineered towards roseoflavin production. Overexpression of the roseoflavin biosynthetic genes rosABC and the flavin transport gene ribM from the native roseoflavin producer Streptomyces davaonensis was evaluated in C. glutamicum. To further link roseoflavin biosynthesis to its riboflavin precursor, the riboflavin kinase gene ribF from both S. davaonensis and C. glutamicum was evaluated, revealing that its overexpression is essential for enhancing roseoflavin production. The final engineered strain CgRose6 achieved a roseoflavin titer of 17.4 ± 1.5 mg/L and a volumetric productivity of 0.36 ± 0.03 mg/L·h when cultivated in glucose minimal medium supplemented with thiamine, a relevant coenzyme for roseoflavin biosynthesis. These production values are the highest reported by a non-native RoF producer to date and demonstrate the feasibility of using C. glutamicum as a platform for sustainable roseoflavin production, opening avenues for scalable biosynthesis of this valuable antimicrobial compound.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.